<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0124-7107</journal-id>
<journal-title><![CDATA[Universidad y Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Univ. Salud]]></abbrev-journal-title>
<issn>0124-7107</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Nariño]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0124-71072023000200003</article-id>
<article-id pub-id-type="doi">10.22267/rus.232502.302</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Con qué medicamentos están siendo tratados los pacientes con trastorno afectivo bipolar en Colombia]]></article-title>
<article-title xml:lang="en"><![CDATA[Which drugs are being treated patients with bipolar affective disorder in Colombia]]></article-title>
<article-title xml:lang="pt"><![CDATA[Com quais medicamentos os pacientes com transtorno afetivo bipolar estão sendo tratados na Colômbia?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[Jorge Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machado-Duque]]></surname>
<given-names><![CDATA[Manuel E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Calderón]]></surname>
<given-names><![CDATA[Viviana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Tecnológica de Pereira-Audifarma SA Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia ]]></institution>
<addr-line><![CDATA[Pereira ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Universitaria Autónoma de las Américas Grupo Biomedicina ]]></institution>
<addr-line><![CDATA[Pereira ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2023</year>
</pub-date>
<volume>25</volume>
<numero>2</numero>
<fpage>27</fpage>
<lpage>32</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0124-71072023000200003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0124-71072023000200003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0124-71072023000200003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  El trastorno bipolar (TB) es una condición psiquiátrica grave caracterizada por alteraciones progresivas en las funciones sociales y cognitivas.  Objetivo:  Determinar cuáles son los medicamentos con que se está tratando a un grupo de pacientes con diagnóstico de TB, afiliados al Sistema de Salud de Colombia.  Materiales y métodos:  Estudio de corte para identificar prescripciones de medicamentos de pacientes ambulatorios de cualquier edad y sexo con TB, a partir de una base de datos poblacional de dispensaciones. Se consideraron variables sociodemográficas, clínicas y farmacológicas buscando medicamentos en indicaciones aprobadas y no aprobadas por agencias reguladoras.  Resultados:  Se identificaron 1334 pacientes, con edad media de 40,2±18,5 años y 50% eran mujeres. Un total de 809 (60,6%) pacientes eran tratados en monoterapia principalmente con ácido valproico (286/615 pacientes, 46,4%), quetiapina (259/525, 49,3%) y Carbonato de Litio (98/275, 35,6%). Las combinaciones más comunes de fármacos para su tratamiento fueron ácido valproico más quetiapina (n=162, 12,1%), ácido valproico más risperidona (n=73, 5,5%) y carbonato de litio más quetiapina (n=62, 4,6%). El 57,4% (n=766) tenían prescripciones de fármacos con indicaciones no aprobadas.  Conclusiones:  Los pacientes con TB son tratados principalmente en monoterapia y más de la mitad estaba recibiendo fármacos en indicaciones no aprobadas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Bipolar disorder (BP) is a serious psychiatric condition characterized by progressive changes in social and cognitive functions.  Objective: To determine which medications are being used to treat a group of patients diagnosed with BP who receive treatment from the Colombian Health System.  Materials and methods: Cross-sectional study to identify medication prescriptions of outpatients (regardless of their age) using a population database. Sociodemographic, clinical, and pharmacological variables were considered, searching for medications that are both approved and not approved by regulatory agencies.  Results: 1,334 patients were identified, who had a mean age of 40.2±18.5 years, 50% of which were women. A total of 809 (60.6%) patients followed monotherapy, mainly using valproic acid (286/615 patients, 46.4%), quetiapine (259/525, 49.3%), and lithium carbonate (98/275, 35.6%). The most common combination of medications to treat these patients were valproic acid combined with quetiapine (n=162, 12.1%), valproic acid combined with risperidone (n=73, 5.5%), and lithium carbonate combined with quetiapine (n=62, 4,6%). 57.4% (n=766) of patients had prescriptions with non-approved medications.  Conclusions: BP patients are mostly treated with monotherapy and more than half of them received drugs that are not approved.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução:  O transtorno bipolar (TB) é uma condição psiquiátrica grave caracterizada por alterações progressivas nas funções sociais e cognitivas.  Objetivo:  Determinar quais medicamentos estão sendo usados &#8203;&#8203;para tratar um grupo de pacientes diagnosticados com TB, vinculados ao Sistema de Saúde da Colômbia.  Materiais e métodos:  Estudo transversal para identificação de prescrições de medicamentos para pacientes ambulatoriais de qualquer idade e sexo com TB, a partir de um banco de dados populacional de dispensações. Foram consideradas variáveis &#8203;&#8203;sociodemográficas, clínicas e farmacológicas, buscando medicamentos em indicações aprovadas e não aprovadas pelos órgãos reguladores.  Resultados:  Foram identificados 1.334 pacientes, com média de idade de 40,2 ± 18,5 anos, sendo 50% mulheres. Um total de 809 (60,6%) pacientes foram tratados em monoterapia principalmente com ácido valpróico (286/615 pacientes, 46,4%), quetiapina (259/525, 49,3%) e carbonato de lítio (98/275, 35,6%). As combinações medicamentosas mais comuns para seu tratamento foram ácido valpróico mais quetiapina (n=162, 12,1%), ácido valpróico mais risperidona (n=73, 5,5%) e carbonato de lítio mais quetiapina (n=62, 5,5%).4,6 %). 57,4% (n=766) tinham prescrições de medicamentos com indicações não aprovadas.  Conclusões:  Os pacientes com TB são tratados principalmente com monoterapia e mais da metade estava recebendo medicamentos em indicações não aprovadas.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Trastorno bipolar]]></kwd>
<kwd lng="es"><![CDATA[Carbonato de Litio]]></kwd>
<kwd lng="es"><![CDATA[trastornos psicóticos]]></kwd>
<kwd lng="es"><![CDATA[antipsicóticos]]></kwd>
<kwd lng="es"><![CDATA[farmacoepidemiología]]></kwd>
<kwd lng="en"><![CDATA[Bipolar disorder]]></kwd>
<kwd lng="en"><![CDATA[Lithium Carbonate]]></kwd>
<kwd lng="en"><![CDATA[psychotic disorders]]></kwd>
<kwd lng="en"><![CDATA[antipsychotic agents]]></kwd>
<kwd lng="en"><![CDATA[pharmacoepidemiology]]></kwd>
<kwd lng="pt"><![CDATA[Transtorno bipolar]]></kwd>
<kwd lng="pt"><![CDATA[Carbonato de Lítio]]></kwd>
<kwd lng="pt"><![CDATA[espectro da esquizofrenia e outros transtornos psicóticos]]></kwd>
<kwd lng="pt"><![CDATA[antipsicóticos]]></kwd>
<kwd lng="pt"><![CDATA[farmacoepidemiologia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bipolar Disorder]]></article-title>
<source><![CDATA[Prim Care]]></source>
<year>2016</year>
<volume>43</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>269-84</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Lahera]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lalucat]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez-Liria]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<collab>En representacion del Grupo Elaborador de la Guia</collab>
<article-title xml:lang=""><![CDATA[Guía de práctica clínica sobre el trastorno bipolar: tratamiento farmacológico y psicosocial]]></article-title>
<source><![CDATA[Med Clin]]></source>
<year>2013</year>
<volume>141</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Grossman]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Harrow]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bonner-Jackson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Faull]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic and prognostic significance of Schneiderian first-rank symptoms: a 20-year longitudinal study of schizophrenia and bipolar disorder]]></article-title>
<source><![CDATA[Compr Psychiatry]]></source>
<year>2011</year>
<volume>52</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>126-31</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Merikangas]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[J-P]]></given-names>
</name>
<name>
<surname><![CDATA[Kessler]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sampson]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative]]></article-title>
<source><![CDATA[Arch Gen Psychiatry]]></source>
<year>2011</year>
<volume>68</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>241-51</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vos]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Flaxman]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Naghavi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Michaud]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ezzati]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2012</year>
<volume>380</volume>
<numero>9859</numero>
<issue>9859</issue>
<page-range>2163-96</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social de Colombia</collab>
<source><![CDATA[Encuesta Nacional de Salud Mental]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Haddad]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bipolar disorder]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2012</year>
<volume>345</volume>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogilvie]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Morant]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Goodwin]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The burden on informal caregivers of people with bipolar disorder]]></article-title>
<source><![CDATA[Bipolar Disord]]></source>
<year>2005</year>
<volume>7</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>25-32</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<collab>National Collaborating Centre for Mental Health (UK)</collab>
<source><![CDATA[Bipolar Disorder: The NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care]]></source>
<year>2014</year>
<publisher-loc><![CDATA[London (GBR) ]]></publisher-loc>
<publisher-name><![CDATA[The British Psychological Society and The Royal College of Psychiatrists]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zarabanda-Suárez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García-Montes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Salcedo-Jarabo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lahera-Forteza]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trastorno bipolar]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2015</year>
<volume>11</volume>
<numero>85</numero>
<issue>85</issue>
<page-range>5075-85</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cipriani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barbui]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Salanti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rendell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Stockton]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2011</year>
<volume>378</volume>
<numero>9799</numero>
<issue>9799</issue>
<page-range>1306-15</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowland]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Marwaha]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology and risk factors for bipolar disorder]]></article-title>
<source><![CDATA[Ther Adv Psychopharmacol]]></source>
<year>2018</year>
<volume>8</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>251-69</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsuchiya]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Byrne]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mortensen]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors in relation to an emergence of bipolar disorder: a systematic review]]></article-title>
<source><![CDATA[Bipolar Disord]]></source>
<year>2003</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>231-42</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[de Queiroz]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pagnin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pezawas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Angst]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cassano]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and burden of bipolar disorders in European countries]]></article-title>
<source><![CDATA[Eur Neuropsychopharmacol]]></source>
<year>2005</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>425-34</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kroon]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Wohlfarth]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Dieleman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sutterland]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Storosum]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Denys]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence rates and risk factors of bipolar disorder in the general population: a population-based cohort study]]></article-title>
<source><![CDATA[Bipolar Disord]]></source>
<year>2013</year>
<volume>15</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>306-13</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pfennig]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of bipolar disorders]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2005</year>
<volume>46</volume>
<numero>^s4</numero>
<issue>^s4</issue>
<supplement>4</supplement>
<page-range>8-13</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Post]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Yatham]]></surname>
<given-names><![CDATA[LN]]></given-names>
</name>
<name>
<surname><![CDATA[Vieta]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Berk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nierenberg]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beyond evidence-based treatment of bipolar disorder: Rational pragmatic approaches to management]]></article-title>
<source><![CDATA[Bipolar Disord]]></source>
<year>2019</year>
<volume>21</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>650-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fountoulakis]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Grunze]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Vieta]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yatham]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Blier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines]]></article-title>
<source><![CDATA[Int J Neuropsychopharmacol]]></source>
<year>2017</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>180-95</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Daglas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dandash]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Yücel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hallam]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quetiapine v lithium in the maintenance phase following a first episode of mania: randomised controlled trial]]></article-title>
<source><![CDATA[Br J Psychiatry]]></source>
<year>2017</year>
<volume>210</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>413-21</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Velosa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dursun]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Kapczinski]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[de Azevedo Cardoso]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clozapine in bipolar disorder A systematic review and meta-analysis]]></article-title>
<source><![CDATA[J Psychiatr Res]]></source>
<year>2020</year>
<volume>125</volume>
<page-range>21-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toffol]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hätönen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tanskanen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lönnqvist]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wahlbeck]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Joffe]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients A nationwide registry-based prospective cohort study]]></article-title>
<source><![CDATA[J Affect Disord]]></source>
<year>2015</year>
<volume>183</volume>
<page-range>159-65</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ando]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Koike]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shimodera]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fujito]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sawada]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Terao]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lithium Levels in Tap Water and the Mental Health Problems of Adolescents: An Individual-Level Cross-Sectional Survey]]></article-title>
<source><![CDATA[J Clin Psychiatry]]></source>
<year>2017</year>
<volume>78</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>e252-6</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Post]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The New News about Lithium: An Underutilized Treatment in the United States]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>2018</year>
<volume>43</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1174-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baldessarini]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Leahy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Arcona]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gause]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Hennen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders]]></article-title>
<source><![CDATA[Psychiatr Serv]]></source>
<year>2007</year>
<volume>58</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>85-91</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Duque]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Alzate-Carvajal]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zapata-Castañeda]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perfil de utilización del carbonato de litio en pacientes con trastorno afectivo bipolar en 25 ciudades de Colombia]]></article-title>
<source><![CDATA[Biomedica]]></source>
<year>2017</year>
<volume>37</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>43-50</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bachmann]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Aagaard]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bernardo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brandt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cartabia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Clavenna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International trends in clozapine use: a study in 17 countries]]></article-title>
<source><![CDATA[Acta Psychiatr Scand]]></source>
<year>2017</year>
<volume>136</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>37-51</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borrelli]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[EY]]></given-names>
</name>
<name>
<surname><![CDATA[Caffrey]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clozapine and hematologic adverse reactions: Impact of the Risk Evaluation and Mitigation Strategy program]]></article-title>
<source><![CDATA[Ment Health Clin]]></source>
<year>2020</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>70-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
